These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 18650621)

  • 1. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Nukui Y; Picozzi VJ; Traverso LW
    Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
    Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
    Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
    J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.
    Chauffert B; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L
    Ann Oncol; 2008 Sep; 19(9):1592-9. PubMed ID: 18467316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
    Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Picozzi VJ; Kozarek RA; Traverso LW
    Am J Surg; 2003 May; 185(5):476-80. PubMed ID: 12727570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
    Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
    Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
    Iott MJ; Corsini MM; Miller RC
    Clin J Oncol Nurs; 2008 Aug; 12(4):599-605. PubMed ID: 18676327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.